Document is current

Article History

Received: 8 April 2021

Accepted: 4 November 2021

First Online: 18 November 2021

Declarations

:

: This trial has received ethical approval from the London - Harrow Research Ethics Committee (19/LO/1461) and the Health Research Authority (HRA) in the United Kingdom. Written informed consent to participate will be obtained from all participants.

: Not applicable.

: This trial received funding from AstraZeneca, Cambridge, UK. G.D.S. declares educational grants from Pfizer, AstraZeneca, and Intuitive Surgical; consultancy fees from Pfizer, Merck, EUSA Pharma, and CMR Surgical; travel expenses from Pfizer; and speaker fees from Pfizer. S.J.W. has received travel support from Ipsen. E.S. declares being a co-founder and shareholder of Lucida Medical, consultancy fees from Amazon and speaker fees from GSK. S.U., M.G.T, R.S., G.Y. and J.A.N.S. declare no competing interests. T.E. was employed by and has stock in AstraZeneca, is employed by and has stock in Roche, has received research support from AstaZeneca, Bayer and Pfizer. K.F. has received advisory, consultancy or speaker fees from ESAI, Ipsen, Roche, Novartis, Merck, Pfizer, Eusa, BMS, conference support from Novartis, Ipsen and EUSA and institutional research funding from Roche, Merck, Exelixis. B.V. has received advisory, consultancy or speaker fees from Bristol Myers Squibb (BMS), Eisai, EUSA pharma, Ipsen, Merck Sorono, Merck Sharp & Dohme (MSD), Pfizer; conference support from Ipsen and Institutional research funding from Exelixis, Ipsen, MSD, Pfizer. A.P. has received advisory, consultancy or speaker fees from Eisai, BMS, Ipsen, MSD, Novartis, Roche, Astellas, Bayer, and Pfizer. Conference support from Pfizer, Ipsen, MSD, Roche, Astellas. Research funding from MSD. F.A.G. has research grants from GSK, research support from GE Healthcare and has consulted for AstraZeneca. M.C.O. has received research funding from Lilly. JS is an employee and stockholder in AstraZeneca, Cambridge, UK and a stockholder in GSK.